Sr. QC Analyist or QC Specialist - San Francisco, CA | Biospace
Get Our FREE Industry eNewsletter

Sr. QC Analyist or QC Specialist

FibroGen, Inc.

Apply
Location:
San Francisco, CA
Posted Date:
8/4/2017
Position Type:
Full time
Job Code:
Salary:
Required Education:
Other
Areas of Expertise Desired:
Quality Control,

Job Description

Located in San Francisco, FibroGen seeks a Sr QC Analyst or QC Specialist to support our roxadustat program.


Duties include:
•   Perform analytical testing of various drug substances, drug products and other materials according to approved methodologies using HPLC, GC and other techniques.
•   Responsible for following all appropriate SOPs, methods, policies and safety guidelines and training of other QC analysts as requested.
•   Responsible for preparing reagents, samples and equipment according to SOP and maintaining instrumentation and lab facilities.
•   Responsible for completing and reviewing laboratory documentation in a cGMP compliant manner.
•   Special projects and other duties as assigned.

Requirements

Requirements:
•   BS in chemistry, biochemistry or related field or equivalent
•   4 to 6 years laboratory experience with chromatography analyses
•   2 to4 years’ experience in the pharmaceutical or related filed with GMP experience
•   Good knowledge and experience with HPLC techniques, experience with dissolution testing and good general chromatography knowledge.
•   Good knowledge and understanding of GMP guidelines.
•   Good technical understanding of specific analytical techniques.



FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.  Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in CKD. Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne’s muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com